ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
BörsenkürzelADMA
Name des UnternehmensADMA Biologics Inc
IPO-datumOct 17, 2013
CEOMr. Adam S. Grossman
Anzahl der mitarbeiter677
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse465 State Route 17
StadtRAMSEY
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl07446
Telefon12014785552
Websitehttps://www.admabiologics.com/
BörsenkürzelADMA
IPO-datumOct 17, 2013
CEOMr. Adam S. Grossman
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten